← GLP-1 receptor agonists × glycemic control

SynthesisThe Journal of clinical endocrinology and metabolism2020

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.

Ildiko Lingvay et al.PubMed ↗Full text ↗Publisher ↗

  • OW semaglutide 1 mglooks good hereLower long-term blood sugar, lower body weight.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

OW semaglutide 1 mg went with lower long-term blood sugar

−0.61percentage points−0.72 to −0.49

OW semaglutide 1 mg vs OD empagliflozin 25 mg

As reported

difference −0.61 %, 95% CI −0.72 to −0.49 · the paper's word: mean HbA1c

Correlation, not cause

OW semaglutide 1 mg went with lower body weight

−1.65kg−2.22 to −1.08

OW semaglutide 1 mg vs OD empagliflozin 25 mg

As reported

difference −1.65 kg, 95% CI −2.22 to −1.08

Who was studied, and how

1,405people with type 2 diabetes, in this paper

Already taking OW semaglutide 1 mg, or nottheir own situation, not assigned

on OW semaglutide 1 mg
OD empagliflozin 25 mg

OW semaglutide 1 mg went with lower long-term blood sugar−0.61

OW semaglutide 1 mg went with lower body weight−1.65

correlation, not a test

the abstract, start to end

… (estimated treatment difference: -0.61%-point [95% confidence interval (CI): -0.72; -0.49] and -1.65 kg [95% CI: -2.22; -1.08], …

← favours treatmentfavours comparator →
could be chance
Mean HbA1cOW semaglutide 1 mg vs OD empagliflozin 25 mg
−0.61−0.72 to −0.49
Body weightOW semaglutide 1 mg vs OD empagliflozin 25 mg
−1.65−2.22 to −1.08
GLP-1 receptor agonistsGlycemic controlBody weight & composition
1 / 4

10 papers cite it

2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 32827435